key: cord-0050019-8bfjpmln
authors: Suto, Eriko G.; Mabuchi, Yo; Toyota, Saki; Taguchi, Miyu; Naraoka, Yuna; Itakura, Natsumi; Matsuoka, Yoh; Fujii, Yasuhisa; Miyasaka, Naoyuki; Akazawa, Chihiro
title: Advantage of fat-derived CD73 positive cells from multiple human tissues, prospective isolated mesenchymal stromal cells
date: 2020-09-15
journal: Sci Rep
DOI: 10.1038/s41598-020-72012-8
sha: 248e410074bc8ed8eb4c133fb28808418e9cd592
doc_id: 50019
cord_uid: 8bfjpmln

Somatic stem cells have been isolated from multiple human tissues for their potential usefulness in cell therapy. Currently, mesenchymal stromal cells (MSCs) are prepared after several passages requiring a few months of cell culture. In this study, we used a prospective isolation method of somatic stem cells from gestational or fat tissues, which were identified using CD73 antibody. CD73-positive population from various tissues existed individually in flowcytometric pattern, especially subcutaneous fat- and amniotic-derived cells showed the highest enrichment of CD73-positive cells. Moreover, the cell populations isolated with the prospective method showed higher proliferative capacity and stem cell marker expression, compared to the cell populations which isolated through several passages of culturing whole living cells: which we named “conventional method” in this paper. Furthermore, the therapeutic potential of CD73-positive cells was evaluated in vivo using a mouse model of pulmonary fibrosis. After intranasal administration, murine CD73-positive cells reduced macrophage infiltration and inhibited fibrosis development. These results suggest that further testing using CD73-positive cells may be beneficial to help establish the place in regenerative medicine use.

| (2020) 10:15073 | https://doi.org/10.1038/s41598-020-72012-8 www.nature.com/scientificreports/ a tissue that can be readily accessed with minimal damage to the donor and also contains a high percentage of CD73-positive population. Toward this end, we isolated CD73-positive cells from various human tissues, including subcutaneous fat, amnion, chorion, villus, and umbilical cord. Using flow cytometry, we evaluated the stem cell characteristics of each population, including the colony-forming ability, proliferation, and expression of MSC markers. To further evaluate the potential of CD73-positive cells as a practical source for cell transplant therapy, we established a mouse model of pulmonary fibrosis using bleomycin (BLM), and examined the impact of intranasal transplantation of CD73-positive cells derived from mouse subcutaneous fat on fibrosis attenuation and on infiltration of inflammatory cells into the lungs.

Comparison of CD73-positive cells from tissues of the same patients. Subcutaneous fat and placenta were collected from 10 patients who underwent repeat caesarean section, and perirenal fat was collected as visceral fat from 10 patients during nephrectomy (Fig. 1a) . The tissues were cut into pieces within 2 h after the operation and treated with 0.2% collagenase for 1 h (Fig. 1b) . After filtration, the collected cells were stained with fluorescent-labelled antibodies targeting the mesenchymal cell surface markers CD73, CD29, CD44, CD73, CD90, CD271, CD31, CD45, and CD235a. Dead and doublet cells were gated out, and CD73-positive cells were retained. The percentage of CD73-positive cells from the subcutaneous fat was 14.87 ± 3.09%, which differed from that in visceral fat, 2.04 ± 0.46% ( Fig. 1c and Supplementary Fig. S1 ). Tissues from the placenta (chorion, amnion, umbilical cord, and villus) showed distinct percentages of CD73 + cells (Fig. 1c) . The proportion appears to be the highest in the amnion and the lowest in the UC. Consistently, CD73-positive cells from the subcutane- www.nature.com/scientificreports/ ous fat and amnion rarely contained hematopoietic cells such as leukocytes or erythrocytes. Interestingly, the size of CD73-positive cells also differed depending on the tissue source (Fig. 1c, Bottom) .

The CD73-positive fraction enriches colony-forming and proliferating cells. A total of 2,000 cells isolated from each tissue were seeded in 10-cm plates and cultured for 14 days, and colony numbers were counted after crystal violet staining. As shown in Fig. 2a ,b and supplemental Fig. 2 , colony-forming units from the visceral fat, subcutaneous fat, chorion, and villus were enriched in CD73-positive cells, and more MSCs were isolated using the prospective isolation method than that obtained with the conventional method. In line with the results of flow cytometry (Fig. 1c) , amnion comprised a large population of CD73-positive cells, although they were predominantly non-adherent cells (Fig. 2a,b and supplemental Fig. 2 ). However, compared to the cells isolated using the conventional whole-living cell method, more proliferative and adherent cells could be effectively harvested with our prospective isolation approach (Fig. 2c ). CD73-positive cells from each wet tissue were counted (Fig. 2d) . Depend on tissue amount, it can be calculated estimated cell number after culturing CD73-positive cells. Fig. 3 ), the same cells highly expressed MSC markers, especially CD44 and CD90. This effect was particularly evident for subcutaneous fat. Moreover, prospective isolated cells from the subcutaneous fat maintained the expression of these markers even after culturing (suffix "_Cultured CD73 + "). Although cells isolated with the conventional method (suffix "_Conventional") also expressed MSC markers after culturing, the expression levels were markedly lower than those of the prospective isolated cells.

Therapeutic potential of CD73-positive cells for pulmonary fibrosis. BLM is commonly used for cancer treatment but has a well-known side effect of pulmonary toxicity. Therefore, BLM is widely used for inducing experimental pulmonary fibrosis in mice 16 . In this study, BLM (5 U/kg) was transnasally administered to mice four times (Fig. 4a) , and changes in body weight and lung histological sections were analyzed to confirm the development of fibrosis. The BLM group lost significantly more weight compared to the phosphatebuffered saline (PBS)-treated control group (Fig. 4b) . Histological analysis further revealed that BLM-treated lungs exhibited alveolar wall thickening, increased collagen deposition, and alveolar wall destruction with air space enlargement ( 

We previously proposed a prospective isolation method for the effective selection of human BM-MSCs based on CD73 expression 14 . In this study, we further demonstrate that in addition to BM-MSCs, fat or placental MSCs could also be isolated with this prospective isolation method using CD73 antibody. Moreover, we found clear differences in CD73 expression among cells isolated from various tissues, even from the same donors.

Although the precise reason for the difference in CD73-positive cell enrichment in different tissues is currently unclear, the results reflect both individual and tissue effects. To overcome this heterogeneity, we harvested tissues from patients undergoing secondary caesarean sections, and only visceral fat was harvested from patients during perirenal tumorectomy. The visceral and subcutaneous fat showed a greater number of colony-forming cells expressing CD73, indicating a higher CD73-positive cell population in the fat with greater colony-forming ability compared to those of other tissues. In addition to the CD73-positive population ratio, the cell size, cytoplasmic organization, and proliferation rate of these cells showed clear differences among tissues. Even between the fat tissues, MSC markers showed much higher expression in the cells of subcutaneous fat compared with those of the visceral fat. Similarly, there were clear differences in the colony-forming rate and CD73-positive population between the amnion and chorion of the placental tissues. These results suggest tissue-specific characteristics of CD73-positive MSCs, along with notable heterogeneity among individuals for enrichment in the subcutaneous www.nature.com/scientificreports/ fat and amnion. As clinical studies use MSCs derived from various tissues 10, 11, 15 , our results highlight the importance of considering the potential different characteristics of the cells depending on the source tissue, which could impact the therapeutic efficacy. CD73-positive cells exhibited CFU-F ability in varying degrees between donors as shown in supplemental Fig. 2 . Nonetheless, all CD73-positive population showed high colony forming ability irrespective of ages or tissues. We believe that our prospective isolating method permits stably harvesting of effective cells for transplantation. In this study, mesenchymal cell marker expression varied among tissues and the isolating method. With respect to the source tissue, the chorion, villus, and umbilical cord of the placenta rarely expressed MSC markers before isolation, whereas the amnion, visceral fat, and subcutaneous fat showed slight expression. After prospective isolation based on CD73 antibody, the placental tissue-derived CD73-postive cells expressed the stem cell marker levels of CD29 and CD90. Prospective isolated visceral fat and subcutaneous fat showed different expression patterns from the other tissues, but were more similar to each other. With respect to the isolation method, the prospective-isolated CD73-positive cells from the subcutaneous fat highly expressed MSC markers such as CD44, CD90, and CD271 compared to conventionally isolated cells. The expression of these markers was also maintained after culturing, and remained at higher levels than conventionally isolated subcutaneous cells. Interestingly, conventionally isolated cells from each tissue located in different clusters based on cell sorting, whereas the prospective isolated cells were all more similar to each other. This indicates that the prospective isolation method could facilitate harvesting homogeneous cells from various tissues.

From a practical perspective, we also found that transplantation of CD73-positive cells isolated from the subcutaneous fat of mice suppressed BLM inhalation-induced lung fibrosis in mice. Fibrosis is the end stage of multiple reactions leading to signaling pathways and dysregulation of inflammatory cells 16 . Pulmonary fibrosis is a progressive lung disease characterized by interstitial fibrosis with a decreasing lung volume 17 . The mechanisms underlying fibrosis progression in cases of idiopathic pulmonary fibrosis (IPF) remain unclear, but appear to involve an excessive immunoreaction. Our results indicate that MSCs have potential to target to the injured area, and to further promote immune tolerance and tissue repair through complex pathways, although the precise mechanism remains to be elucidated. Previous reports have examined the therapeutic effects of human MSCproduced exosomes in a bleomycin-induced model of pulmonary fibrosis and the role of human MSC-secreted soluble factors in a model of emphysesma 18, 19 . In the present our study, it is likely that an additional experimental system of transferring human adipose-derived CD73 cells themselves or their secretions into a mouse model will be necessary. However, due to fundamental species differences and immune rejection, we were unable to transplant the human CD73-positive cells into our model. In vivo experiments using the new experimental model and analysis of exosome differences in different tissues will have important implications for our future experiments.

To obtain highly purified CD73-positive cells is the primary issues for human clinical trials. Currently, widely used methods for antibody-based purification are flow cytometry (FACS) and magnetic activated cell sorting (MACS) 20 . FACS is the preferred method when very high purity of the desired population is required, and when the target cell population expresses a very low level of the identifying marker or when cell populations. Although FACS is frequently used in the laboratory usages, a clinical grade (Good Manufacturing Practice; GMP-grade) flow cytometry has several disadvantages such as low speed, a GMP facility space and cost consuming. MACS has been used in several clinical cases under the guidelines of GMP. CD73 has an advantage that a single antibody can yield cells with high purity. Serial passage of CD73-positive cells over the MACS columns would result in further enrichment. It would be beneficial in clinical application.

Overall, our results showed that CD73-positive cells were effectively harvested from the subcutaneous fat with MSC characteristics. Furthermore, transplantation of these cells suppressed fibrosis and inflammation in pulmonary fibrosis model mice. Although clinical translation of these results requires further detailed research owing to the large gap between a mouse disease model and human disease, our results indicate that CD73positive cells might provide a new strategy for treating and managing pulmonary fibrosis. Our result indicates that the interstitial pneumonia after COVID-19 infection should be considered for the candidate disease. Further investigations into the detailed mechanisms of pulmonary fibrosis could lead to the development of a safe and effective therapy. Colony-forming unit fibroblast assay. The colony-forming unit fibroblast assay was performed by culturing 2000 sorted cells on a non-coated 100-mm dish for 14 days in DMEM containing 20% FBS (Gibco), 1% penicillin/streptomycin, and 20 ng/mL basic fibroblast growth factor (Repro Cell, Kanagawa, Japan). The medium was changed twice per week. Colonies containing more than 50 cells were counted.

Mice. Male C57BL/6JJcl mice (9 weeks of age) were purchased from Japan SLC Inc. and C57BL/6-Tg CAG-EGFP mice (8 weeks of age) were purchased from CLEA Japan, Inc. All experimental protocols were approved by the animal committee of Tokyo Medical and Dental University, Japan. All methods were conducted in strict accordance with the approved guidelines of the institutional animal care committee.

Induction of pulmonary fibrosis. The mice were anaesthetized with 1.5-2% isoflurane (FUJIFILM Wako

Pure Chemical) inhalation, and each mouse was set down on its back on an 60°-inclined board with a rubber band running across the upper incisors. BLM-sulfate (5 U/kg body weight; Nippon-Kayaku) in 25 μL PBS was then administered into the left nostril four times to induce lung fibrosis 21 . Control mice were injected with an equal volume of PBS in the same manner.

Isolation and transplantation of CD73-positive cells. CD73-positive cells were isolated from the subcutaneous fat tissue of 8-week-old C57BL/6-Tg CAG-EGFP mice. Similar to the isolation from human tissues, for collagenase treatments, the subcutaneous fat was chopped and minced in DMEM containing 2% FBS and 2 mg/mL collagenase (FUJIFILM Wako Pure Chemical) for 1 h at 37 °C with shaking. The cells were then diluted in HBSS containing 2% FBS, 10 mM HEPES, and 1% penicillin/streptomycin (Gibco). PI fluorescence was used to remove dead cells, and APC-conjugated anti-CD73 (Biolegend) was used for single-colour staining, followed by sorting with flow cytometry analysis on the FACS Aria II system (BD). The cells were cultured in MSCs medium as previously described 14 . After culture for 14 days, non-adherent cells were removed, and the cells (7.0 × 10 4 in 25 μL of PBS) were administered to the mice through transnasal injection 14 and 21 days after the first BLM administration. Control animals received an equal volume of PBS.

The mice were sacrificed at days 14 and 28 after BLM administration. The mice were anaesthetised with isoflurane inhalation, and the BALF was collected by instilling 10 mL PBS into the trachea via a 25-gauge needle. The BALF was centrifuged at 800 g for 3 min at 4 °C, and then diluted in HBSS containing 2% FBS, 10 mM HEPES, and 1% penicillin/streptomycin. The BALF was then stained with PE-Cy7-conjugated anti-CD11b (BD) for counting of infiltrating macrophages.

Hematoxylin and eosin staining. After deparaffinization and rehydration, 5-μm-thick lung tissue sections were stained with hematoxylin solution for 2 min at 50 °C and then rinsed in PBS. The sections were stained with 0.5% eosin solution (FUJIFILM Wako Pure Chemical) for 1 min followed by dehydration with graded alcohol and cleared in xylene. eVG staining. After deparaffinization and rehydration, 5-μm-thick lung sections were dipped in 1% acid ethanol (1% HCl in 70% ethanol), stained with Resorcin fuchsin (Muto Pure Chemicals, Tokyo, Japan) for 1 h, and rinsed in PBS. The lung tissues were then stained with hematoxylin solution for 5 min and then with van Gieson solution for 10 min, followed by dehydration with graded alcohol and clearing in xylene. Statistical analysis. Data were analysed using the Mann-Whitney U test for variables showing a nonparametric distribution, and with unpaired and two-tailed Student t-tests or one-way analysis of variance to compare two or more than two groups, respectively, for variables showing a parametric distribution. All statistical analyses were performed using GraphPad prism 7 software (San Diego, CA, USA). P values < 0.05 were considered statistically significant.

All data generated or analyzed during this study are included in this published article and its Supplementary Information files. www.nature.com/scientificreports/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.

Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs

Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105 + cells

Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies

Multilineage potential of adult human mesenchymal stem cells

Immunosuppressive effects of mesenchymal stem cells: Involvement of HLA-G

Bone regeneration in a massive rat femur defect through endochondral ossification achieved with chondrogenically differentiated MSCs in a degradable scaffold

Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis

Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice

Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke

Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial

Biological characterization of long-term cultured human mesenchymal stem cells

Prospective isolation of murine and human bone marrow mesenchymal stem cells based on surface markers

Prospectively isolated mesenchymal stem/stromal cells are enriched in the CD73+ population and exhibit efficacy after transplantation

Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles

Cellular and molecular mechanisms of fibrosis

An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes

Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of

Isolation methods for human CD34 subsets using fluorescent and magnetic activated cell sorting: an in vivo comparative study

Mouse models of bleomycin-induced pulmonary fibrosis

We thank all of the lab members for supporting this study. This work was financially supported by Grants-in-Aid (KAKENHI for young 

The authors declare no competing interests.

Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-72012 -8.Correspondence and requests for materials should be addressed to C.A.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.